Key facts
- This page summarizes Mark E. Hensley's Form 4 filing for HERON THERAPEUTICS, INC. /DE/ (HRTX).
- 0 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 29 Apr 2025, 12:47.
Mark E. Hensley - 28 Apr 2025 Form 4 Insider Report for HERON THERAPEUTICS, INC. /DE/ (HRTX)
- Reporting relationship
- Chief Operating Officer
- Issuer ticker
- HRTX
- Reported as of
- 28 Apr 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 29 Apr 2025, 12:47:33 UTC
- Next SEC filing
- 07 May 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/Kathryn Lester Attorney-in-fact for Mark E. Hensley
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Mark E. Hensley filed Form 4 for HERON THERAPEUTICS, INC. /DE/ (HRTX) on 29 Apr 2025.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
HRTX
holding
Derivative
Employee Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 500,000
- Date
- 28 Apr 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 500,000
- Exercise price
- $2.33
- Footnotes
- F1
HRTX
holding
Derivative
Employee Performance Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 900,000
- Date
- 28 Apr 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 900,000
- Exercise price
- $2.33
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The stock option vests and becomes exercisable with respect to 125,000 shares on the first anniversary of the date of grant, followed by 375,000 shares vesting ratably each month over the subsequent three years, such that 500,000 options will be fully vested on the four year anniversary of the date of grant.
Footnote F2
The stock option vests and becomes exercisable with respect to escalating portions of the option grant upon the Issuer's stock price reaching certain pre-established levels ranging from $4.50 to $9.00 per share, subject to the Reporting Person's continued service to the Issuer through the vesting date.